HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)
Hepatocellular Carcinoma
DRUG: Lenvatinib|DRUG: Sorafenib|PROCEDURE: Hepatic arterial infusion chemotherapy
Overall survival, Overall survival, Time Frame: 12 months
Time to progression, Time to progression, Time Frame: 12 months|Adverse Events, [Time Frame: 30 days]|Progression Free Survival (PFS), Time Frame: 12 months
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)